Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Obesity drugs - especially Novo Nordic's Ozempic - dominated healthcare headlines in 2024, but Matt Miskin of John Hancock ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Wall Street is pointing slightly lower in early trading but is on track to close the week with solid gains on healthy ...

Here are some of the major companies whose stocks moved on the week’s news.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...